• STING agonist-1: Mechanistic Insights in B Cell Activation R

  2026-05-20

  STING agonist-1 is a high-purity, DMSO-soluble small molecule designed for robust activation of the STING pathway in immunology research. It enables precise dissection of type I interferon responses and B cell-mediated antitumor mechanisms. Its role is pivotal in studies of tertiary lymphoid structure dynamics and cancer immunotherapy.

• STING agonist-1: Optimizing B Cell Activation in Tumor Immun

  2026-05-20

  STING agonist-1 empowers researchers to dissect and modulate innate immune signaling, unlocking new dimensions in cancer immunotherapy and inflammation research. This article delivers actionable workflows, protocol enhancements, and troubleshooting strategies grounded in the latest mechanistic insights for robust, reproducible experiments.

• Cy3 Goat Anti-Mouse IgG (H+L) Antibody: Protocols and QC Gui

  2026-05-19

  The Cy3 Goat Anti-Mouse IgG (H+L) Antibody addresses the need for sensitive, specific detection of mouse IgG in immunofluorescence, flow cytometry, and western blot assays. It is best suited for applications requiring signal amplification and robust visualization of mouse-derived primary antibodies, but is not recommended for diagnostic or clinical use due to its research-only designation.

• Structure-Based Screening Identifies NSP15 Inhibitors in SAR

  2026-05-19

  The referenced study leverages structure-based virtual screening of natural compounds to identify potent inhibitors of SARS-CoV-2 non-structural protein 15 (NSP15). By pinpointing thymopentin and oleuropein as stable NSP15 binders, the research advances the search for targeted COVID-19 antivirals and highlights the value of natural product libraries for rapid drug discovery.

• Epalrestat: Advanced Aldose Reductase Inhibitor for Oxidativ

  2026-05-18

  Epalrestat, a potent aldose reductase inhibitor supplied by APExBIO, unlocks new experimental possibilities in neurodegenerative and diabetic complication models through its unique dual-action mechanism—polyol pathway inhibition and KEAP1/Nrf2 pathway activation. This guide details optimized protocols, troubleshooting, and comparative applications to elevate oxidative stress and Parkinson’s disease research.

• Epalrestat: Aldose Reductase Inhibitor for Translational Pat

  2026-05-18

  Epalrestat empowers researchers to dissect the polyol pathway and its impact on diabetic complications and cancer metabolism. Its unique solubility and validated action on the KEAP1/Nrf2 axis unlock robust, reproducible workflows for oxidative stress and neuroprotection studies.

• Phosphatase Inhibitor Cocktail 2: Enabling High-Fidelity Pro

  2026-05-17

  Discover how Phosphatase Inhibitor Cocktail 2 empowers rigorous protein phosphorylation preservation for high-fidelity biochemical assays. This article uniquely bridges assay parameter optimization with practical innovations from recent chemical proteomics research.

• Optimized hiPSC Platelet Differentiation: Protocol Advances

  2026-05-16

  This study presents a systematically optimized protocol for differentiating functional platelets from human induced pluripotent stem cells (hiPSCs), integrating higher embryoid body input, refined media, and targeted small molecule supplementation. The approach significantly improves yield, reduces cost, and identifies new potential for kinase inhibitors in stem cell-derived platelet production.

• Haloprogin: Mechanistic Insights and Strategic Advances

  2026-05-15

  This article explores Haloprogin’s mechanistic underpinnings, translational protocol guidance, and emerging value in antifungal and antimicrobial research. It integrates evidence from peer-reviewed studies, outlines experimental and clinical workflow parameters, and positions Haloprogin (1,2,4-trichloro-5-((3-iodoprop-2-yn-1-yl)oxy)benzene) as an advanced tool for infection model innovation. The discussion highlights comparative efficacy, cross-model versatility, and forward-looking research opportunities, with credible citations and actionable references for translational scientists.

• Ferritin-Based Hybrid Vaccine: M2e and SARS-CoV-2 Epitope In

  2026-05-15

  This study introduces a ferritin-based hybrid protein particle vaccine that co-displays influenza A M2e and SARS-CoV-2 spike protein tandem epitopes, assembled in E. coli. The platform achieves enhanced immunogenicity and functional antibody responses, offering a promising approach for next-generation combination vaccines.

• Bedaquiline: Diarylquinoline Antibiotic for Advanced TB & Ca

  2026-05-14

  Bedaquiline stands out as a diarylquinoline antibiotic uniquely positioned for tackling both multi-drug resistant tuberculosis and cancer stem cell metabolism. Its dual mechanism and robust evidence base empower translational workflows and next-generation experimental designs.

• Epalrestat: Applied Protocols for Aldose Reductase Inhibitio

  2026-05-14

  Epalrestat stands out as a robust aldose reductase inhibitor pivotal for research into diabetic complications and neurodegenerative disease models. This article delivers actionable experimental workflows, reference-driven innovations, and troubleshooting strategies, empowering scientists to achieve reproducible results across polyol pathway and oxidative stress studies.

• Niclosamide: Precision Tool for STAT3-Driven Cancer Models

  2026-05-13

  Explore how Niclosamide, a potent STAT3 pathway inhibitor, enables high-fidelity cancer research through targeted cell cycle arrest and apoptosis assays. This article uniquely bridges molecular pharmacology, advanced protocol design, and actionable insights from ATRX-deficient glioma studies.

• Cinoxacin: Mechanism, Spectrum, and Pharmacokinetics in UTI

  2026-05-13

  This article examines the foundational work by Scavone et al. on Cinoxacin, a quinolone antibiotic, highlighting its mechanism of bacterial DNA synthesis inhibition, activity against Gram-negative urinary pathogens, and distinctive pharmacokinetics. The findings offer critical insights for urinary tract infection and antibiotic resistance research, with practical implications for laboratory and translational studies.

• Evaluating Topotecan Versus Carboplatin Regimens in Ovarian

  2026-05-12

  This Cochrane review critically evaluates the efficacy and safety of topotecan-containing regimens compared to standard carboplatin/paclitaxel combinations in ovarian cancer. The findings clarify that adding topotecan does not significantly improve survival outcomes but does increase toxicity, emphasizing the need for evidence-based regimen selection in preclinical and translational research.

16559 records 1/1104 page Next 12345 下5页 Last page